2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118497
    BMS 182874 153042-42-3 99.85%
    BMS 182874 is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research.
    BMS 182874
  • HY-119727
    WNK-IN-1 2125724-72-1 98.87%
    WNK-IN-1 (compound 7) is a ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor (IC50=95 nM). WNK-IN-1 can be used to regulate cardiovascular homeostasis.
    WNK-IN-1
  • HY-120979
    NO-Losartan A 791122-48-0 98.33%
    NO-Losartan A (compound 2a) displays vasorelaxing effects, due to the release of NO, and antagonized the vasocontractile effects of Angiotensin II (HY-13948), with potency values similar to that of Losartan (HY-17512).
    NO-Losartan A
  • HY-121795
    Pravastatin lactone 85956-22-5 99.20%
    Pravastatin lactone is a potent HMG-CoA inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis.
    Pravastatin lactone
  • HY-121955
    FW1256 117089-08-4
    FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and induces cell apoptosis. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.
    FW1256
  • HY-122235
    MRL-24 393794-17-7 99.58%
    MRL-24 is a PPARγ agonist. MRL-24 can be used in metabolic disease related research.
    MRL-24
  • HY-12273R
    DMH-1 (Standard) 1206711-16-1 99.78%
    DMH-1 (Standard) is the analytical standard of DMH-1. DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.
    DMH-1 (Standard)
  • HY-123349
    5α-Hydroxy-6-keto cholesterol 13027-33-3 ≥99.0%
    5α-Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. 5α-Hydroxy-6-keto cholesterol inhibits cholesterol synthesis with an IC50 of 350 nM.
    5α-Hydroxy-6-keto cholesterol
  • HY-123468
    HA-1004 91742-10-8 99.04%
    HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models.
    HA-1004
  • HY-123494
    BRD0418 1565827-99-7 99.22%
    BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
    BRD0418
  • HY-125437
    3-Epidehydrotumulosic acid 167775-54-4 98.14%
    3-Epidehydrotumulosic acid has inhibitory activity against AAPH-induced lysis of red blood cells.
    3-Epidehydrotumulosic acid
  • HY-125772
    Acetyl podocarpic acid anhydride 344327-48-6 99.0%
    Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels.
    Acetyl podocarpic acid anhydride
  • HY-129056
    Melagatran 159776-70-2 99.31%
    Melagatran is a reversible, selective, orally active direct inhibitor of thrombin with a Ki of 2 nM. Melagatran binds directly to the active site of thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1. Melagatran reduces fibrin deposition in organs, alleviates ischemic brain damage, and reduces the size of advanced atherosclerotic lesions. Melagatran can be used in the study of cardiovascular disease (coronary thrombosis, atherosclerosis) and ischemic brain damage.
    Melagatran
  • HY-134769
    OPC-163493 1644467-84-4 99.34%
    OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease.
    OPC-163493
  • HY-135121
    Ethacizine hydrochloride 57530-40-2 99.25%
    Ethacizine hydrochloride (Ethacizin; NIK-244) is a longer-lasting Class Ic antiarrhythmic agent than Flecainide. Ethacizine hydrochloride (Ethacizin; NIK-244) inhibits the depolarizing current responsible for the intraatrial and His-Purkinje-ventricular conduction.
    Ethacizine hydrochloride
  • HY-136832
    Noribogaine hydrochloride 110514-35-7 99.90%
    Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity.
    Noribogaine hydrochloride
  • HY-138647
    TGP-377/421 16752-89-9 98.17%
    TGP-377/421 (Targapre-miR-377/421) is a potent miR-377 and miR-421 inhibitor that binds a functional site in both miRNAs.
    TGP-377/421
  • HY-14184S
    Macitentan-d4 1258428-05-5 99.85%
    Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan-d4
  • HY-14233S
    Omecamtiv mecarbil-d8 99.57%
    Omecamtiv mecarbil-d8 is the deuterium labeled Omecamtiv mecarbil. Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil-d8
  • HY-147203
    5-HT2B antagonist-1 393129-91-4 99.90%
    5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 value of 33.4 nM. 5-HT2B antagonist-1 can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease.
    5-HT2B antagonist-1
Cat. No. Product Name / Synonyms Application Reactivity